相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Quantifying Drug Combination Synergy along Potency and Efficacy Axes
Christian T. Meyer et al.
CELL SYSTEMS (2019)
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
Andreas Weihofen et al.
NEUROBIOLOGY OF DISEASE (2019)
Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease
Veselin Grozdanov et al.
ANNALS OF NEUROLOGY (2019)
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054
Miroslaw Brys et al.
MOVEMENT DISORDERS (2019)
Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment
Jeffrey Pido-Lopez et al.
SCIENTIFIC REPORTS (2019)
Oligodendroglial α-synucleinopathy-driven neuroinflammation in multiple system atrophy
Alana Hoffmann et al.
BRAIN PATHOLOGY (2019)
Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease
Marta Garcia-Miralles et al.
MOLECULAR NEUROBIOLOGY (2019)
Dementia with Lewy bodies: an update and outlook
Tiago Fleming Outeiro et al.
MOLECULAR NEURODEGENERATION (2019)
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
Darren J. Schofield et al.
NEUROBIOLOGY OF DISEASE (2019)
Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network
Simona Gribaudo et al.
STEM CELL REPORTS (2019)
Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms
Maria Masnata et al.
ACTA NEUROPATHOLOGICA (2019)
Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer
Elysia C. Saputra et al.
CANCER RESEARCH (2018)
Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease
Ashley S. Harms et al.
EXPERIMENTAL NEUROLOGY (2018)
A New Venue of TNF Targeting
Sophie Steeland et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy
Kurt A. Jellinger
JOURNAL OF ALZHEIMERS DISEASE (2018)
Evidence for Compromised Insulin Signaling and Neuronal Vulnerability in Experimental Model of Sporadic Alzheimer's Disease
Smriti Gupta et al.
MOLECULAR NEUROBIOLOGY (2018)
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies
Chao Peng et al.
NATURE (2018)
Distinct alpha-Synuclein strains and implications for heterogeneity among alpha-Synucleinopathies
Chao Peng et al.
NEUROBIOLOGY OF DISEASE (2018)
Neurotrophic factors hold promise for the future of Parkinson's disease treatment: is there a light at the end of the tunnel?
Ava Nasrolahi et al.
REVIEWS IN THE NEUROSCIENCES (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
Martin Kallab et al.
FRONTIERS IN NEUROSCIENCE (2018)
Immunosuppressants and risk of Parkinson disease
Brad A. Racette et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Early microglial activation and peripheral inflammation in dementia with Lewy bodies
Ajenthan Surendranathan et al.
BRAIN (2018)
Recent advances in combinatorial drug screening and synergy scoring
Tea Pemovska et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Developing and validating Parkinson's disease subtypes and their motor and cognitive progression
Michael Lawton et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease
Jeffrey Pido-Lopez et al.
SCIENTIFIC REPORTS (2018)
The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease
Alice J. White et al.
FRONTIERS IN NEUROLOGY (2018)
alpha-Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models
Jingjing Cheng et al.
ASN NEURO (2018)
Clinical and Imaging Features of Multiple System Atrophy: Challenges for an Early and Clinically Definitive Diagnosis
Hirohisa Watanabe et al.
JOURNAL OF MOVEMENT DISORDERS (2018)
Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype
Bei Wang et al.
SCIENCE IMMUNOLOGY (2018)
Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration
Michel Goedert et al.
BRAIN (2017)
First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk et al.
MOVEMENT DISORDERS (2017)
IKKβ and mutant huntingtin interactions regulate the expression of IL-34: implications for microglial-mediated neurodegeneration in HD
Ali Khoshnan et al.
HUMAN MOLECULAR GENETICS (2017)
Dendritic cell and antigen dispersal landscapes regulate T cell immunity
Michael Y. Gerner et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
T cells from patients with Parkinson's disease recognize α-synuclein peptides
David Sulzer et al.
NATURE (2017)
Multiple system atrophy: insights into a rare and debilitating movement disorder
Florian Krismer et al.
NATURE REVIEWS NEUROLOGY (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Laquinimod treatment in the R6/2 mouse model
Gisa Ellrichmann et al.
SCIENTIFIC REPORTS (2017)
The Synucleinopathies: Twenty Years On
Michel Goedert et al.
JOURNAL OF PARKINSONS DISEASE (2017)
α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
Ashley S. Harms et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
Elvira Valera et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Proteasome impairment by alpha-synuclein
Lisa Zondler et al.
PLOS ONE (2017)
Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration
Michel Goedert et al.
BRAIN (2017)
Combined immunotherapy with anti-insulin resistance therapy as a novel therapeutic strategy against neurodegenerative diseases
Yoshiki Takamatsu et al.
NPJ PARKINSONS DISEASE (2017)
Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Visualization of prion-like transfer in Huntington's disease models
Anne H. P. Jansen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial
Howard E. Gendelman et al.
NPJ PARKINSONS DISEASE (2017)
Human-to-mouse prion-like propagation of mutant huntingtin protein
Iksoo Jeon et al.
ACTA NEUROPATHOLOGICA (2016)
Rationale for anti-GITR cancer immunotherapy
Deborah A. Knee et al.
EUROPEAN JOURNAL OF CANCER (2016)
Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons
Dagmar E. Ehrnhoefer et al.
EXPERIMENTAL NEUROLOGY (2016)
A critical role for alpha-synuclein in development and function of T lymphocytes
Afshin Shameli et al.
IMMUNOBIOLOGY (2016)
The Effect of Fragmented Pathogenic α-Synuclein Seeds on Prion-like Propagation
Airi Tarutani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
Lucianne Dobson et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies
Natalia P. Rocha et al.
MEDIATORS OF INFLAMMATION (2016)
Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
Marta Garcia-Miralles et al.
SCIENTIFIC REPORTS (2016)
Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease
Arlene I. Ramsingh et al.
HUMAN MOLECULAR GENETICS (2015)
Specific in vivo knockdown of protein function by intrabodies
Andrea L. J. Marschall et al.
MABS (2015)
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Markus Mandler et al.
MOLECULAR NEURODEGENERATION (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-β oligomer-treated hippocampal neurons
Oliver Takach et al.
NEUROBIOLOGY OF AGING (2015)
Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers
Marios Politis et al.
NEUROBIOLOGY OF DISEASE (2015)
Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease
Amber L. Southwell et al.
NEUROBIOLOGY OF DISEASE (2015)
Transcellular spreading of huntingtin aggregates in the Drosophila brain
Daniel T. Babcock et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Propagation of prions causing synucleinopathies in cultured cells
Amanda L. Woerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease
Kenneth E. Ugen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Parkinson's Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort
Michael Lawton et al.
JOURNAL OF PARKINSONS DISEASE (2015)
Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
Elizabeth E. Evans et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D
Elizabeth E. Evans et al.
ONCOIMMUNOLOGY (2015)
Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson's Disease
Md Shahaduzzaman et al.
PLOS ONE (2015)
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials
Markus Mandler et al.
ACTA NEUROPATHOLOGICA (2014)
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation
Ulrike Traeger et al.
BRAIN (2014)
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future
Lisa M. Sedger et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease
Han-Yun Hsiao et al.
HUMAN MOLECULAR GENETICS (2014)
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease
Enara Herran et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2014)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Dora Games et al.
JOURNAL OF NEUROSCIENCE (2014)
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
Lei Lu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors
Andrea Crotti et al.
NATURE NEUROSCIENCE (2014)
Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice
Veronica Lindstrom et al.
NEUROBIOLOGY OF DISEASE (2014)
Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: Feasibility study
Anahit Ghochikyan et al.
NEUROSCIENCE LETTERS (2014)
α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration
Hien T. Tran et al.
CELL REPORTS (2014)
The Role of the Immune System in Huntington's Disease
Gisa Ellrichmann et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease
Han-Yun Hsiao et al.
HUMAN MOLECULAR GENETICS (2013)
Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type α-Synuclein and Reduces the Pathology in an α-Synuclein Model of LBD
Brian Spencer et al.
MOLECULAR THERAPY (2013)
Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7
Udo Rueb et al.
PROGRESS IN NEUROBIOLOGY (2013)
Caspase Functions in Cell Death and Disease
David R. McIlwain et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Bozic et al.
ELIFE (2013)
Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor
Jan Thoene et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Alpha-synuclein's degradation in vivo Opening a new (cranial) window on the roles of degradation pathways in Parkinson disease
Darius Ebrahimi-Fakhari et al.
AUTOPHAGY (2012)
Insulin Promotes Neuronal Survival via the Alternatively Spliced Protein Kinase CδII Isoform
Andre Apostolatos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression
Andreas Weiss et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis
Rina Aharoni et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Eun-Jin Bae et al.
JOURNAL OF NEUROSCIENCE (2012)
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Louise M. Collins et al.
NEUROPHARMACOLOGY (2012)
Insight into the mechanism of laquinimod action
W. Brueck et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Huntington's disease: from molecular pathogenesis to clinical treatment
Christopher A. Ross et al.
LANCET NEUROLOGY (2011)
Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease
Torsten Falk et al.
NEUROSCIENCE LETTERS (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments
David C. Butler et al.
PLOS ONE (2011)
Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies
He-Jin Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Roles of Sema4D-Plexin-B1 Interactions in the Central Nervous System for Pathogenesis of Experimental Autoimmune Encephalomyelitis
Tatsusada Okuno et al.
JOURNAL OF IMMUNOLOGY (2010)
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study
M. Gurevich et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice
Abigail Snyder-Keller et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2010)
A Futility Study of Minocycline in Huntington's Disease
Heidi Schwarz et al.
MOVEMENT DISORDERS (2010)
α-Synuclein and dopamine at the crossroads of Parkinson's disease
Lara Lourenco Venda et al.
TRENDS IN NEUROSCIENCES (2010)
Peripheral cytokines profile in Parkinson's disease
M. Reale et al.
BRAIN BEHAVIOR AND IMMUNITY (2009)
Induction of chemokines, MCP-1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction
Swetha K. Godavarthi et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease
Amber L. Southwell et al.
JOURNAL OF NEUROSCIENCE (2009)
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease
Chuan-En Wang et al.
HUMAN MOLECULAR GENETICS (2008)
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
Maria Bjorkqvist et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease
Melissa K. Mccoy et al.
JOURNAL OF NEUROINFLAMMATION (2008)
Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity
Amber L. Southwell et al.
JOURNAL OF NEUROSCIENCE (2008)
Second consensus statement on the diagnosis of multiple system atrophy
S. Gilman et al.
NEUROLOGY (2008)
TNF-α inhibition as a treatment strategy for neurodegenerative disorders:: New drug candidates and targets
David Tweedie et al.
CURRENT ALZHEIMER RESEARCH (2007)
Microglial activation in presymptomatic Huntington's disease gene carriers
Yen F. Tai et al.
BRAIN (2007)
Calpain-cleavage of α-synuclein -: Connecting proteolytic processing to disease-linked aggregation
Brian M. Dufty et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Lack of minocycline efficiency in genetic models of Huntington's disease
Stephane Mievis et al.
NEUROMOLECULAR MEDICINE (2007)
Sema4D/plexin-B1 activates GSK-3β through R-Ras GAP activity, inducing growth cone collapse
Yuri Ito et al.
EMBO REPORTS (2006)
Microglial activation correlates with severity in Huntington disease - A clinical and PET study
N. Pavese et al.
NEUROLOGY (2006)
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
EC Stack et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2006)
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
A Gerhard et al.
NEUROBIOLOGY OF DISEASE (2006)
Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations
WX Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Microglial activation and dopamine terminal loss in early Parkinson's disease
Y Ouchi et al.
ANNALS OF NEUROLOGY (2005)
Minocycline in phenotypic models of Huntington's disease
K Bantubungi et al.
NEUROBIOLOGY OF DISEASE (2005)
Activation of the IκB kinase complex and nuclear factor-κB contributes to mutant Huntingtin neurotoxicity
A Khoshnan et al.
JOURNAL OF NEUROSCIENCE (2004)
The semaphorin 4D receptor plexin-B1 is a GTPase activating protein for R-Ras
I Oinuma et al.
SCIENCE (2004)
Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B
JR Basile et al.
CANCER RESEARCH (2004)
The promise of minocycline in neurology
VW Yong et al.
LANCET NEUROLOGY (2004)
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats
HS Yang et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease
E Diguet et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
PM Steed et al.
SCIENCE (2003)
Signalling pathways of the TNF superfamily: A double-edged sword
BB Aggarwal
NATURE REVIEWS IMMUNOLOGY (2003)
Minocycline and doxycycline are not beneficial in a model of Huntington's disease
DL Smith et al.
ANNALS OF NEUROLOGY (2003)
DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype
TW Miller et al.
MOLECULAR THERAPY (2003)
Plexin-B1 directly interacts with PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology
JM Swiercz et al.
NEURON (2002)
TNF receptor subtype signalling: Differences and cellular consequences
DJ MacEwan
CELLULAR SIGNALLING (2002)
The CD100-CD72 interaction: a novel mechanism of immune regulation
A Kumanogoh et al.
TRENDS IN IMMUNOLOGY (2001)
The TNF and TNF receptor superfamilies: Integrating mammalian biology
RM Locksley et al.
CELL (2001)
Early and progressive accumulation of reactive microglia in the Huntington disease brain
E Sapp et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2001)
Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: A novel mechanism for regulating B cell signaling
A Kumanogoh et al.
IMMUNITY (2000)
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
M Chen et al.
NATURE MEDICINE (2000)
Fourteen and counting: unraveling trinucleotide repeat diseases
CJ Cummings et al.
HUMAN MOLECULAR GENETICS (2000)
Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease
Y Hasegawa et al.
ACTA NEUROLOGICA SCANDINAVICA (2000)
分享论文
